Cargando…

LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells in tumor microenvironment, which suppress antitumor immunity. Expansion of various MDSC subpopulations is closely associated with poor clinical outcomes in cancer. Lysosomal acid lipase (LAL) is a key enzyme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ting, Liu, Sheng, Hanna, Nasser H, Jalal, Shadia, Ding, Xinchun, Wan, Jun, Yan, Cong, Du, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016256/ https://www.ncbi.nlm.nih.gov/pubmed/36914206 http://dx.doi.org/10.1136/jitc-2022-006272

Ejemplares similares

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
por: Gaißler, Andrea, et al.
Publicado: (2023)

Novel role of microphthalmia-associated transcription factor in modulating the differentiation and immunosuppressive functions of myeloid-derived suppressor cells
por: Lee, Aram, et al.
Publicado: (2023)

Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
por: Jiménez-Cortegana, Carlos, et al.
Publicado: (2021)

Activation of mTOR Pathway in Myeloid-derived Suppressor Cells Stimulates Cancer Cell Proliferation and Metastasis in lal−/− Mice
por: Zhao, Ting, et al.
Publicado: (2014)

Establishment of lal-/- Myeloid Lineage Cell Line That Resembles Myeloid-Derived Suppressive Cells
por: Ding, Xinchun, et al.
Publicado: (2015)

Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment
por: Väyrynen, Juha P, et al.
Publicado: (2021)

Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers
por: Li, Jinming, et al.
Publicado: (2023)

Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients
por: Huber, Veronica, et al.
Publicado: (2021)

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
por: Sui, Qiaoqi, et al.
Publicado: (2021)

Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer
por: Sprooten, Jenny, et al.
Publicado: (2021)

Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer
por: Lv, Kunpeng, et al.
Publicado: (2023)

Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer
por: Guo, Yongdong, et al.
Publicado: (2023)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
por: Posner, Atara, et al.
Publicado: (2023)

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy
por: Sun, Guangshun, et al.
Publicado: (2022)

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer
por: Bai, Yuezong, et al.
Publicado: (2022)

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Egelston, Colt, et al.
Publicado: (2021)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer
por: Seo, Incheol, et al.
Publicado: (2021)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
por: Yao, Yao, et al.
Publicado: (2020)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study
por: Huang, Weicai, et al.
Publicado: (2023)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
por: Porcelli, Letizia, et al.
Publicado: (2021)

Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
por: Shui, Irene M., et al.
Publicado: (2022)

Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions
por: Abdulrahman, Ziena, et al.
Publicado: (2022)

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
por: Roussot, Nicolas, et al.
Publicado: (2023)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
por: de Joode, Karlijn, et al.
Publicado: (2023)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors
por: Kobayashi, Tomoko, et al.
Publicado: (2021)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
por: So, WeiQing Venus, et al.
Publicado: (2023)

SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response
por: Tanagala, Kranthi Kiran Kishore, et al.
Publicado: (2022)

Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
por: Wu, Shaowei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8t33vh0niejd8kjdu8d4gjp8d8